{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:59:55Z","timestamp":1790312395686,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Polycystic ovary syndrome (PCOS) is a heterogeneous condition associated with reproductive, metabolic, pregnancy, and psychological morbidity across the life course. Polyendocrine metabolic ovarian syndrome (PMOS) was recently proposed through a multistep global consensus process, with implementation across guidelines and health systems still under way. This Perspective argues that the clinical value of the naming proposal will depend on whether it redirects care beyond ovarian morphology and body size. Insulin resistance can serve as an actionable management hub linking reproductive endocrine dysfunction with longer-term metabolic risk in a substantial subgroup, but it is neither universal, the sole cause of the syndrome, nor a diagnostic criterion. Routine fasting insulin measurement or homeostatic model assessment of insulin resistance should therefore not be introduced as diagnostic requirements. Instead, we propose a weight-neutral, insulin-sensitivity-centered, life-course pathway aligned with existing guideline recommendations. Glycemic status, lipids, blood pressure, cardiovascular risk, pregnancy planning, psychological health, and risk-directed liver assessment should be considered according to clinical guidance without using BMI as an exclusion criterion. Lifestyle intervention should be evaluated through metabolic, functional, reproductive, and quality-of-life outcomes, not weight change alone. Metformin and GLP-1 receptor agonists should remain confined to guideline-supported indications and evidence limitations. Whether PMOS improves risk recognition, guideline adherence, patient experience, or continuity of care remains to be established.<\/jats:p>","DOI":"10.3389\/fendo.2026.1909495","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:26:50Z","timestamp":1790310410000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From PCOS to PMOS: reframing the clinical pathway around insulin sensitivity and weight-neutral metabolic risk"],"prefix":"10.3389","volume":"17","author":[{"given":"Haoyang","family":"Jiao","sequence":"first","affiliation":[{"name":"China Institute for History of Medicine and Medical Literature, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Guo","sequence":"additional","affiliation":[{"name":"Graduate School, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Liu","sequence":"additional","affiliation":[{"name":"China Institute for History of Medicine and Medical Literature, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad463","article-title":"Recommendations from the 2023 International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome","volume":"108","author":"Teede","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-024-07607-x","article-title":"Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis","volume":"310","author":"Salari","year":"2024","journal-title":"Arch Gynecol Obstet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100494","article-title":"Changes in the prevalence of polycystic ovary syndrome in China over the past decade","volume":"25","author":"Yang","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"B4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12902-024-01717-y","article-title":"Diabetes screening among women with polycystic ovary syndrome: a descriptive study of commercial claims, 2011\u20132019","volume":"24","author":"Vollmer","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103287","article-title":"Polycystic ovary syndrome perspectives from patients and health professionals on clinical features, current name, and renaming: a longitudinal international online survey","volume":"84","author":"Teede","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1064937","article-title":"A systematic review of lived experiences of people with polycystic ovary syndrome highlights the need for holistic care and co-creation of educational resources","volume":"13","author":"Lau","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00717-8","article-title":"Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process","volume":"407","author":"Teede","year":"2026","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2040","article-title":"Renaming PCOS\u2014a two-state solution","volume":"98","author":"Dunaif","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2017.09.030","article-title":"Polycystic ovary syndrome, an enigmatic syndrome begging for a name change","volume":"108","author":"Rosenwaks","year":"2017","journal-title":"Fertil Steril"},{"key":"B10","unstructured":"Polyendocrine Metabolic Ovarian Syndrome: New Name to Improve Diagnosis and Care of Condition Affecting 170 Million Women Worldwide\n          \n          2026"},{"key":"B11","unstructured":"PCOS is Now PMOS: Understanding the Name Change\n          \n          2026"},{"key":"B12","unstructured":"PCOS Name Change\n          \n          2026"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01057-w","article-title":"Polycystic ovary syndrome as a metabolic disease","volume":"21","author":"Helvaci","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The pathogenesis of polycystic ovary syndrome: the hypothesis of PCOS as functional ovarian hyperandrogenism revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1056\/NEJMct0707092","article-title":"Metformin for the treatment of the polycystic ovary syndrome","volume":"358","author":"Nestler","year":"2008","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/des463","article-title":"Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulinaemic clamp","volume":"28","author":"Stepto","year":"2013","journal-title":"Hum Reprod"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew243","article-title":"Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies","volume":"31","author":"Cassar","year":"2016","journal-title":"Hum Reprod"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex308","article-title":"Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes","volume":"32","author":"Tosi","year":"2017","journal-title":"Hum Reprod"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2017.1342165","article-title":"Beta cell function and insulin resistance in lean cases with polycystic ovary syndrome","volume":"33","author":"Pande","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031378","article-title":"Insulin sensitivity in women with polycystic ovary syndrome","volume":"89","author":"Vrbikova","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmy007","article-title":"Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression","volume":"24","author":"Kakoly","year":"2018","journal-title":"Hum Reprod Update"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.12.018","article-title":"Risk of type 2 diabetes is increased in nonobese women with polycystic ovary syndrome: the National Health Insurance Service-National Sample Cohort Study","volume":"115","author":"Ryu","year":"2021","journal-title":"Fertil Steril"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab658","article-title":"Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome","volume":"107","author":"Falzarano","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030856","article-title":"Non-Alcoholic Fatty Liver Disease in patients with polycystic ovary syndrome: a systematic review, meta-analysis, and meta-regression","volume":"12","author":"Manzano-Nunez","year":"2023","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1038\/s41467-024-49749-1","article-title":"Systematic review and meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome","volume":"15","author":"Bahri Khomami","year":"2024","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033572","article-title":"2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: insights from a systematic review and meta-analysis on elevated clinical cardiovascular disease in polycystic ovary syndrome","volume":"13","author":"Tay","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2016.07.043","article-title":"Metabolic screening in patients with polycystic ovary syndrome is largely underutilized among obstetrician-gynecologists","volume":"215","author":"Dhesi","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4158\/EP13414.OR","article-title":"Practice patterns in screening for metabolic disease in women with PCOS of diverse race-ethnic backgrounds","volume":"20","author":"Mott","year":"2014","journal-title":"Endocr Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00606","article-title":"Exercise interventions in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"11","author":"Patten","year":"2020","journal-title":"Front Physiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsampl.2023.100024","article-title":"Comparison of selected exercise training modalities in the management of PCOS: a systematic review and meta-analysis to inform evidence-based guidelines","volume":"2","author":"Colombo","year":"2023","journal-title":"JSAMS Plus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.09.006","article-title":"Randomized comparison of the influence of dietary management and\/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome","volume":"96","author":"Nybacka","year":"2011","journal-title":"Fertil Steril"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1589\/jpts.27.2293","article-title":"Benefits of short-term structured exercise in non-overweight women with polycystic ovary syndrome: a prospective randomized controlled study","volume":"27","author":"Turan","year":"2015","journal-title":"J Phys Ther Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/db20-0062","article-title":"Mechanisms underlying absent training-induced improvement in insulin action in lean, hyperandrogenic women with polycystic ovary syndrome","volume":"69","author":"Hansen","year":"2020","journal-title":"Diabetes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4306-3","article-title":"Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome","volume":"60","author":"Sam","year":"2017","journal-title":"Diabetologia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad465","article-title":"Metformin and combined oral contraceptive pills in the management of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"109","author":"Melin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13704","article-title":"Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline","volume":"25","author":"Goldberg","year":"2024","journal-title":"Obes Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01666-6","article-title":"The effectiveness and safety of liraglutide in treating overweight\/obese patients with polycystic ovary syndrome: a meta-analysis","volume":"45","author":"Ge","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvag033","article-title":"GLP-1 receptor agonist treatment in women with polycystic ovary syndrome\u2014a systematic review and meta-analysis","volume":"194","author":"Forslund","year":"2026","journal-title":"Eur J Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex044","article-title":"High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"32","author":"Cooney","year":"2017","journal-title":"Hum Reprod"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmu012","article-title":"Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"20","author":"Barry","year":"2014","journal-title":"Hum Reprod Update"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1909495\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:26:51Z","timestamp":1790310411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1909495\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":41,"alternative-id":["10.3389\/fendo.2026.1909495"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1909495","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1909495"}}